Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:754

Official publication of the Indian Society of Nephrology
 ~   Next article
 ~   Previous article
 ~   Table of Contents

 ~   Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~Related articles
 ~   Citation Manager
 ~   Access Statistics
 ~   Reader Comments
 ~   Email Alert *
 ~   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded200    
    Comments [Add]    
    Cited by others 2    

Recommend this journal


Year : 2012  |  Volume : 22  |  Issue : 3  |  Page : 189-192

Sevelamer carbonate experience in Indian end stage renal disease patients

1 Dialysis Unit, Tamilnad Kidney Research Foundation, Kilpauk, Chennai, India
2 Department of Nephrology and Transplant Medicine, Fortis Hospital, New Delhi, India
3 Department of Nephrology, Pusphawati Singhania Research Institute, New Delhi, India
4 Department of Nephrology, Ezhil Hospital, Tondiarpet, Chennai, India
5 Department of Nephrology, Shree Samarth Hospital, Hrishikesh Medical Foundation 9, Nasik, India
6 Department of Nephrology, Janaki Hospital, Aurangabad, India
7 Department of Nephrology, JSS Hospital, Mysore, Karnataka, India

Correspondence Address:
G Abraham
Tamilnad Kidney Research Foundation, No. 766, Poonamalli High Road, Kilpauk, Chennai 600 010
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-4065.98754

Rights and Permissions

This open label, multicentric, comparative clinical trial was done to compare the efficacy and tolerability of two sevelamer formulations, sevelamer carbonate, and sevelamer hydrochloride, in the treatment of hyperphosphatemia in Indian end stage renal disease (ESRD) patients. A total of 97 ESRD patients on hemodialysis, were enrolled. Patients were randomized to receive either sevelamer carbonate or sevelamer hydrochloride. All patients were evaluated every week for 6 weeks for efficacy and safety variables. Total 88 patients completed the study. After 6 weeks of therapy, there were similar reductions (P<0.0001) in mean serum phosphorus and the CaxP product both the groups. The responder rates for test and reference groups were 75%, 68.18% respectively (P=0.3474). The adverse events reported were nausea, abdominal pain/discomfort, heartburn, constipation, diarrhea, increased prothrombin time, and severe arthritis. No serious adverse events were reported. There was no significant difference between the groups for adverse events and the laboratory parameters. From the results of this multicentric, comparative, randomized clinical study on sevelamer carbonate we can recommend that sevelamer carbonate may be used as a phosphate binder in Indian chronic kidney disease patients.


Print this article     Email this article

Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07